eprintid: 10130689
rev_number: 16
eprint_status: archive
userid: 608
dir: disk0/10/13/06/89
datestamp: 2021-07-06 11:35:50
lastmod: 2022-09-09 08:57:13
status_changed: 2021-07-06 11:35:50
type: article
metadata_visibility: show
creators_name: Chopra, R
creators_name: Preston, GC
creators_name: Keenan, TDL
creators_name: Mulholland, P
creators_name: Patel, PJ
creators_name: Balaskas, K
creators_name: Hamilton, RD
creators_name: Keane, PA
title: Intravitreal injections: past trends and future projections within a UK tertiary hospital
ispublished: pub
subjects: GOSH
subjects: MOOR
divisions: UCL
divisions: B02
divisions: C07
divisions: D08
note: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
abstract: Aims: To describe past trends and future projections for the number of intravitreal injections being administered at a large tertiary hospital in London, United Kingdom. Methods: Retrospective data from Moorfields Eye Hospital were collected using the electronic medical record system. Descriptive statistics were used to visualise overall trends. Time series forecasting was used to predict the number of injections that will be administered up to and including the year 2029. Results: The number of injections has increased nearly 11-fold from 2009 to 2019, with a total of 44,924 injections delivered in 2019. The majority of injections were given for the treatment of neovascular age-related macular degeneration. Aflibercept formed 87% of injections administered in 2019. The number of injections is predicted to continue to increase every year, with nearly 83,000 injections forecasted in the year 2029. Conclusion: The demand for intravitreal injections has increased substantially over the last decade and is predicted to further increase. Healthcare systems will need to adapt to accommodate the high demand. Other solutions may include longer-acting therapies to reduce the treatment burden.
date: 2021-06-14
date_type: published
official_url: https://doi.org/10.1038/s41433-021-01646-3
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1874900
doi: 10.1038/s41433-021-01646-3
lyricists_name: Balaskas, Konstantinos
lyricists_name: Chopra, Reena
lyricists_name: Keane, Pearse
lyricists_id: KBALA95
lyricists_id: RCHOP17
lyricists_id: KPEAR28
actors_name: Chopra, Reena
actors_id: RCHOP17
actors_role: owner
full_text_status: public
publication: Eye
citation:        Chopra, R;    Preston, GC;    Keenan, TDL;    Mulholland, P;    Patel, PJ;    Balaskas, K;    Hamilton, RD;           Chopra, R;  Preston, GC;  Keenan, TDL;  Mulholland, P;  Patel, PJ;  Balaskas, K;  Hamilton, RD;  Keane, PA;   - view fewer <#>    (2021)    Intravitreal injections: past trends and future projections within a UK tertiary hospital.                   Eye        10.1038/s41433-021-01646-3 <https://doi.org/10.1038/s41433-021-01646-3>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10130689/1/s41433-021-01646-3.pdf